JAMA Network
About The Study: According to the results of this population-based surveillance study, during 2024-2025, both maternal respiratory syncytial virus (RSV) vaccine and nirsevimab were estimated to be effective at protecting infants from RSV-associated hospitalizations in their first RSV season, and RSV-associated hospitalization rates in newborns and infants ages 0 to 11 months were reduced by up to half compared to seasons before these products were introduced.
/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.
